This page contains recent news articles, when available, and an overview of but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Background information on

Altus Shares Rise on Partnership Outlook  -  Mar 20, 2008
CNNMoney.comAnalyst Eun Yang maintained a $16 price target while citing the partnership potential for Altus' Trizytek pancreatic insufficiency treatment in patients

Zentase NDA Granted Priority Review  -  Feb 29, 2008
FDA news (subscription),It initiated the submission in June 2007 and was granted fast-track designation by the FDA for the treatment of exocrine pancreatic insufficiency.

Altus Pharmaceuticals Reports Fourth Quarter and Year End 2007 ...  -  Mar 11, 2008
StreetInsider.com (subscription),The efficacy trial is designed to evaluate approximately 150 cystic fibrosis (CF) patients over the age of seven with exocrine pancreatic insufficiency at

Altus Pharmaceuticals Inc. Q4 2007 Earnings Call  -  Mar 11, 2008
Seeking Alpha,Trizytek is the company’s orally administered enzyme replacement therapy currently in Phase 3 development for patient’s with pancreatic insufficiency.

Société générale de financement du Québec invests in TPG Capital's ...  -  Feb 26, 2008
Gouv. du Québec (Communiqués de presse),Its main drugs are used to treat exocrine pancreatic insufficiency (ULTRASE, PANZYTRAT and VIOKASE), certain liver diseases (URSO/URSO 250, URSO FORTE/URSO

Eurand's formulations stack up at the FDA  -  Mar 11, 2008
In-PharmaTechnologist.com,...formulation technologies and a proprietary treatment addressing the estimated $720m worldwide market for exocrine pancreatic insufficiency (EPI).

Eurand Reports Fourth Quarter and Year-end 2007 Key Achievements ...  -  Mar 6, 2008
Primenewswire (press release),Eurand has completed two phase III clinical trials on its lead product candidate, Zentase, intended for the treatment of Exocrine Pancreatic Insufficiency

Glandular Cellular Therapy in Pets  -  Mar 10, 2008
EVLivingPets with exocrine pancreatic insufficiency need additional pancreatic enzymes to digest food and absorb nutrients from the diet.

Axcan Announces Completion of Transaction With TPG Capital  -  Feb 26, 2008
FOXBusiness...such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency.

Detoxification Hazards  -  Mar 7, 2008
Los Angeles Chronicle,Defects of permeability can be caused by intestinal parasites, dysbiosis, impaired digestion, pancreatic insufficiency, food allergies, and the use of

Landry's Restaurants Q4 Loss Narrows On Lower Expenses, Revenue ...  -  Mar 11, 2008
RTT News,...known as ALTU-135, is Altus Pharma's orally administered enzyme replacement therapy under development for patients with pancreatic insufficiency.

Zacks Analyst Blog Highlights: Eurand NV, Cephalon and GlaxoSmithKline  -  Mar 11, 2008
PR-Inside.com (Pressemitteilung),The FDA accepted the NDA filing for the company's lead candidate, Zentase, as a treatment for pancreatic insufficiency in February 2008 and we expect a

Eurand to Present At the Lehman  -  Mar 10, 2008
Ad-Hoc-News (Pressemitteilung),Eurand has completed two phase III clinical trials on itslead product candidate, Zentase(tm), intended for the treatment ofExocrine Pancreatic Insufficiency

Eurand to Present At the Lehman Brothers 11th Annual Global ...  -  Mar 10, 2008
Primenewswire (press release),...on its lead product candidate, Zentase(tm), intended for the treatment of Exocrine Pancreatic Insufficiency and has submitted an NDA for this product.

DJ HUGIN NEWS/Eurand Reports Fourth Quarter and Year-end 2007 Key ...  -  Mar 6, 2008
VisAvis (Pressemitteilung),...its lead proprietary product candidate, Zentase(tm) (EUR-1008), currently being developed for the treatment of exocrine pancreatic insufficiency (EPI).

Family's shopping wish comes true - with style  -  Feb 25, 2008
Fort Wayne Journal Gazette,Symptoms vary from person to person, but Noah has asthma, sleep apnea, epilepsy and pancreatic insufficiency, his mother, Shawn Hughart, said.

Altus Pharma falls after CEO resigns  -  Feb 5, 2008
BusinessWeekIn July, the Food and Drug Administration dealt the company a setback by revoking orphan drug status for Altus' pancreatic insufficiency treatment.

Axcan Pharma Reports Solid Start to Fiscal 2008, With Revenue of ...  -  Jan 31, 2008
FOXBusinessIn April 2004, the FDA formally notified manufacturers of pancreatic insufficiency products that these drugs, which include ULTRASE and VIOKASE,

Axcan Pharma Q1 profit rises to US$22.3M from year-ago US$17.5M  -  Jan 31, 2008
The Canadian Press...such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency.

Bone Complications Due To Cystic Fibrosis Have A Genetic Cause ...  -  Feb 7, 2008
Science Daily (press release)This difference occurs without the pancreatic insufficiency seen clinically and in the absence of steroid treatment. This conclusion clearly defines

Eurand Announces Fourth Quarter 2007 and Year-end Financial ...  -  Feb 4, 2008
FOXBusinessEurand has completed two phase III clinical trials on its lead product candidate, Zentase, intended for the treatment of Exocrine Pancreatic Insufficiency

UPDATE 1-Axcan first-quarter results rise ahead of takeover  -  Jan 31, 2008
ReutersIts Ultrase pancreatic insufficiency treatment contributed $13.9 million, while Canasa, its treatment for active ulcerative proctitis, added $16.7 million.

Vitamin D: Sunshine and So Much More  -  Jan 22, 2008
Mother Earth News,Disorders that interfere with fat absorption include celiac disease, Crohn’s disease, pancreatic insufficiency, liver disease or cystic fibrosis.

Vitamin D insufficiency in children, adolescents, and young adults ...  -  Dec 7, 2007
Am J Clin Nutr (subscription),Background: Cystic fibrosis (CF) with pancreatic insufficiency is associated with poor absorption of fat and fat-soluble vitamins, including vitamin D.

Eurand Completes New Drug Application for Zentase  -  Dec 20, 2007
CNNMoney.comEurand has completed two phase III clinical trials on its lead product candidate, Zentase, for the treatment of Exocrine Pancreatic Insufficiency and has

Axcan Agrees To US$1.3 Bln Buyout By TPG; Stock Soars - Update  -  Nov 29, 2007
RTT News,The company's products include Ultrase, Panzytrat and Viokase, which are used to treat exocrine pancreatic insufficiency diseases. Axcan's URSO/URSO 250,

NCCN Updates Pancreatic Cancer Guidelines  -  Dec 12, 2007
Cancer Consultants (press release),...outlet obstruction; severe tumor-associated abdominal pain; depression, pain, and malnutrition; pancreatic insufficiency; and thromboembolic disease.

Axcan Pharma Continues its Solid Growth Trend, Closing Fiscal 2007 ...  -  Nov 29, 2007
Earthtimes,In April 2004, the United States Food and Drug Administration ("FDA") formally notified manufacturers of pancreatic insufficiency products that these drugs,

CORRECTION FROM SOURCE: Axcan Pharma Inc. Obtains Interim Order ...  -  Dec 20, 2007
FOX News...such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency.

Get Wonderful Information on Cystic Fibrosis  -  Dec 2, 2007
American Chronicle,Treatment of pancreatic insufficiency by replacement of missing digestive enzymes allows the duodenum to properly absorb nutrients and vitamins that would

Eurand Buys SourceCF for $6.6M in Cash  -  Dec 3, 2007
CNNMoney.comEurand has completed two late-stage clinical trials on Zentase, for the treatment of Exocrine Pancreatic Insufficiency, a condition where the pancreas stops

Altus reacquires ALTU-238 growth hormone from Genentech; shares fall  -  Dec 20, 2007
Euro2day,Trizytek - a treatment for pancreatic insufficiency - has a high probability of success in Phase III trials and, ultimately, commercial success.

Eurand Completes Bioavailability Study of Zentase  -  28 Nov 2007
CNNMoney.comEurand has completed two phase III clinical trials on its lead product candidate, Zentase, for the treatment of exocrine pancreatic insufficiency (EPI) and

Eurand NV (EURX) Completes Study on Zentase  -  28 Nov 2007
StreetInsider.com (subscription),...a gastrointestinal bioavailability study on Zentase(tm), Eurand's lead product candidate for the treatment of exocrine pancreatic insufficiency (EPI).

Axcan Pharma to Present at the BMO Capital Markets Focus on ...  -  28 Nov 2007
CNNMoney.com...such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency.

Market Report -- In Play (WIRES)  -  28 Nov 2007
MSN Money...of a gastrointestinal bioavailability study on Zentase, the co's lead product candidate for the treatment of exocrine pancreatic insufficiency.

eurand to present at lazard capital markets 4th annual healthcare ...  -  Nov 20, 2007
CNNMoney.com...zentase, for the treatment of exocrine pancreatic insufficiency and filed a rolling nda for this product which the company anticipates to complete by

altus pharmaceuticals reports third quarter 2007 financial results  -  Nov 7, 2007
Business Wire (press release),...an oral enzyme replacement therapy for cystic fibrosis patients with pancreatic insufficiency. altus' consistent and pure enzyme combination, trizytek,

eurand reports third quarter 2007 key achievements and financial ...  -  Nov 9, 2007
ABN Newswire (press release),...zentase (eur-1008), currently being developed for the treatment of exocrine pancreatic insufficiency (epi), as well as an update on the company's most

altus pharmaceuticals q3 2007 earnings call transcript  -  Nov 7, 2007
Seeking Alpha,...digest porcine free enzymes. trizytek is an oral enzyme replacement therapy for patients with pancreatic insufficiency. during the second quarter,

fresh del monte produce prices public offering of 10 mln ordinary ...  -  Nov 7, 2007
RTT News,...an oral enzyme replacement therapy for cystic fibrosis patients with pancreatic insufficiency. the company expects to report top-line efficacy data from

liquidstockreport.com: novemeber's stocks to watch: (pinksheets ...  -  Nov 1, 2007
Trading Markets (press release),...product is an orally-administered enzyme replacement therapy for the treatment of malabsorption due to exocrine pancreatic insufficiency; and altu-238,

Eurand to Host Official Ceremony for Facility Expansion  -  Sep 27, 2007
CNNMoney.comEurand has completed two phase III clinical trials on its lead product candidate, Zentase, for the treatment of Exocrine Pancreatic Insufficiency and filed

Axcan Licenses Rights to Cx401, an Innovative Biological Product ...  -  Oct 1, 2007
CNNMoney.com...such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency.

Solvay 'still on path' for Creon  -  Aug 21, 2007
US-PharmaTechnologist.com,By Katrina Megget 8/21/2007 - Solvay Pharmaceuticals still believed it was on track for meeting US regulatory deadlines for pancreatic insufficiency drugs

Solvay Pharmaceuticals, Inc. Receives Approvable Letter from FDA ...  -  Aug 20, 2007
American Digital Networks (press release),...suffer from cystic fibrosis and pancreatic insufficiency and we will continue to work with the Agency to gain approval for this life-sustaining drug.

Axcan Pharma to Present at the Thomas Weisel Partners Healthcare ...  -  Aug 23, 2007
CNNMoney.com...such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency.

Cephalon, Inc. to Acquire Amrix(R) - a Eurand Diffucaps(R) Product  -  Aug 23, 2007
CNNMoney.comEurand has completed two phase III clinical trials on its lead product candidate Zentase(TM) for the treatment of Exocrine Pancreatic Insufficiency and

Axcan Pharma (AXCA): Aiding your digestion  -  Aug 16, 2007
Blogging StocksProducts include medicines for exocrine pancreatic insufficiency diseases; cholestatic liver diseases; inflammatory bowel diseases; gastric duodenal ulcers;

Axcan Pharma Sustains Growth in Fiscal 2007, With Record Revenue ...  -  10 Aug 2007
CNNMoney.comIn April 2004, the US Food and Drug Administration ("FDA" or "The Agency") formally notified manufacturers of pancreatic insufficiency products that these

Axcan Pharma Submits Complete New Drug Application for ULTRASE  -  Aug 2, 2007
CNNMoney.comThis submission exemplifies our commitment to providing valuable therapeutic options for significant unmet needs in the pancreatic insufficiency segment of

Eurand Award Honors Achievements in Oral Drug Delivery Research  -  Aug 9, 2007
CNNMoney.comEurand has completed two phase III clinical trials on its lead product candidate Zentase(TM) for the treatment of Exocrine Pancreatic Insufficiency and

Eurand Reports First Half 2007 Key Achievements and Financial Results  -  Aug 3, 2007
CNNMoney.comEurand has completed two Phase III clinical trials on its lead product candidate, Zentase, for the treatment of exocrine pancreatic insufficiency (EPI) and

Axcan Pharma Strengthens its Management Team with the Appointment ...  -  Jul 30, 2007
CNNMoney.com...such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency.

Pharma Blog Watch  -  Jul 11, 2007
FDA news (subscription),...proteins, respectively, that are deficient in [exocrine pancreatic insufficiency] (EPI) patients and that causes poor absorption of essential nutrients

Family embraces its fortune and faith  -  Jul 15, 2007
Louisville Courier-Journal,Occurring in approximately one in every 50000 births, Shwachman-Diamond syndrome, first described in 1964, is characterized by pancreatic insufficiency and

Altus Pharmaceuticals Reports Second Quarter 2007 Results  -  Aug 8, 2007
PharmaLive.com (press release),...trials to evaluate the efficacy and safety of ALTU-135, an oral enzyme replacement therapy for cystic fibrosis patients with pancreatic insufficiency.

FDA Revokes Orphan Drug Status of Altus Pharma's Pancreatic ...  -  Jul 3, 2007
CanadianBusiness.com,Pancreatic insufficiency occurs when the pancreas fails to secrete the sufficient chemicals and enzymes for digestion. It is a rare condition.

Eurand's Zentase(TM) Effective in Treating Exocrine Pancreatic ...  -  Jun 19, 2007
netPR.pl (komunikaty prasowe),Paediatric Drugs (2000; 2 : 205-22) (2) Guidance for Industry Exocrine Pancreatic Insufficiency Drug Products - Submitting NDAs. US Department of Health and

Eurand Files NDA for Zentase(TM) for Exocrine Pancreatic Insufficiency  -  Jun 12, 2007
PR Newswire (press release),...(1) Guidance for Industry Exocrine Pancreatic Insufficiency Drug Products - Submitting NDAs. US Department of Health and Human Services, Food and Drug

Eurand Files New Drug Application With FDA For Zentase Intended ...  -  Jun 12, 2007
RTT News,NV (EURX) announced on Tuesday that it filed new drug application with the FDA for its Zentase for the treatment of Exocrine Pancreatic Insufficiency.

Market Report -- In Play (EURX)  -  Jun 12, 2007
MSN MoneyEurand files NDA for Zentase for exocrine pancreatic insufficiency Co announces that Eurand Pharmaceuticals initiated the rolling submission of its new drug

Abigail needs special care  -  Jun 9, 2007
Lancaster Newspapers,Abigail was diagnosed with diabetes and exocrine pancreatic insufficiency as a puppy. She needs an injection of insulin twice daily, but she tolerates these

Mailers union approves 5-year pact with Globe  -  Jul 3, 2007
Boston Globe,...of the Food and Drug Administration revoked the orphan drug designation granted in 2002 to ALTU-135 for the treatment of pancreatic insufficiency.

Altus Pharmaceuticals Reacquires European Development and ...  -  Jun 11, 2007
Business Wire (press release),ALTU-135, the Company’s orally administered enzyme replacement therapy for patients with pancreatic insufficiency, is manufactured by blending three drug

Midwest Air Group May Traffic Up 21.6%; Sees Lower Q2 EPS ...  -  Jun 12, 2007
RTT News,Files NDA For Zentase To Treat Pancreatic Insufficiency - Quick Facts [EURX] 6/12/2007 8:42:30 AM Eurand NV (EURX) on Tuesday revealed the submission of a

Ailing Sofia Heating Deputy Released, Scandal Runs Wild  -  Apr 27, 2007
Sofia News Agency,Georgi Rogachev spent two months in the prison hospital after he was found to suffer from a number of diseases, including pancreatic insufficiency,

Eurand Announces Positive Phase III Clinical Study Results  -  Apr 4, 2007
PR Newswire (press release),...(1) Guidance for Industry Exocrine Pancreatic Insufficiency Drug Products -Submitting NDAs US Department of Health and Human Services, Food and Drug

Eurand reveals positive phase III data  -  Apr 4, 2007
Pharmaceutical Business ReviewEurand has unveiled positive data from two phase III trials of Zentase for the treatment of exocrine pancreatic insufficiency, a condition associated with

Eurand Announces Positive Phase III Clinical Study Results  -  Apr 5, 2007
Drug Newswire (press release),...phase III clinical trials on its lead product candidate, Zentase(TM), formerly EUR-1008, for the treatment of Exocrine Pancreatic Insufficiency (EPI).

Biotech Day In Review: Roche Buys BioVeris For $600 Million  -  Apr 5, 2007
Seeking Alpha,Eurand, an Italian biotech, said Zentase showed efficacy as a treatment for Exocrine Pancreatic Insufficiency [EPI] in its Phase III trials.

Axcan Pharma to Present at the CIBC World Markets Biotechnology ...  -  Apr 4, 2007
Web Services Journal,...such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency.

Axcan Pharma Outlines Growth Strategy at Annual Meeting of ...  -  28 Feb 2007
SYS-CON Media,...such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency.

Strong Start for Axcan Pharma's Fiscal 2007, With Record Revenue ...  -  Feb 8, 2007
CCNMatthews (press release),In April 2004, the US Food and Drug Administration ("FDA") formally notified manufacturers of pancreatic insufficiency products that these drugs,

Lonza ups the stakes in US and Czech Republic  -  Feb 9, 2007
DrugResearcher.com,ALTU-135 is an orally administered enzyme replacement therapy for patients with pancreatic insufficiency. Phase III clinical trials are planned for this

Axcan to Present at the Merrill Lynch Global Pharmaceutical ...  -  Jan 31, 2007
CCNMatthews (press release),...such as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases and complications related to pancreatic insufficiency.

Search the web for more resources on

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.